Clinical Trial

A Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2059 Powder for Inhalation

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Randomized, double-blind and placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of SYH2059 powder for inhalation after single and multiple doses in healthy subjects. The study is composed of 2 parts. Part 1 is to assess the safety, tolerability and pharmacokinetics of a single ascending dose of SYH2059 powder for inhalation. Part 2 is to assess the safety, tolerability and pharmacokinetics of a multiple ascending dose of SYH2059 powder for inhalation.
Trial Details
NCT Number NCT07510958
Lead Sponsor InnovStone Therapeutics Limited
Conditions Healthy Participants
Enrollment 84 participants
Start Date 2026-03-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-06